A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2
Public ClinicalTrials.gov record NCT03093324. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Study in Subjects With Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objectives of this study are to evaluate the utility of two gastrointestinal (GI) symptom scales (Individual GI Symptom and Impact Scale {IGISIS} and Global GI Symptom and Impact Scale {GGISIS}) in assessing GI tolerability in adult subjects with RRMS after administration of ALKS 8700 or Dimethyl Fumarate (DMF) in Part A, to compare the GI tolerability of ALKS 8700 and DMF in adult subjects with RRMS using IGISIS and GGISIS in Part B, and to Evaluate the safety and tolerability of ALKS 8700 in adult subjects with RRMS in Parts A and B.
Study identification
- NCT ID
- NCT03093324
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 506 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 15, 2017 (Actual)
- Primary completion
- Jun 27, 2019 (Actual)
- Completion
- Jun 27, 2019 (Actual)
- Last update posted
- Jul 14, 2020
2017 – 2019
United States locations
- U.S. sites
- 57
- U.S. states
- 25
- U.S. cities
- 50
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alkermes Investigational Site | Cullman | Alabama | 35058 | — |
| Alkermes Investigational Site | Phoenix | Arizona | 85004 | — |
| Alkermes Investigational Site | Tucson | Arizona | 85704 | — |
| Alkermes Investigational Site | Long Beach | California | 90806 | — |
| Alkermes Investigational Site | San Diego | California | 92103 | — |
| Alkermes Investigational Site | Basalt | Colorado | 81621 | — |
| Alkermes Investigational Site | Centennial | Colorado | 80112 | — |
| Alkermes Investigational Site | Denver | Colorado | 80209 | — |
| Alkermes Investigational Site | Middlebury | Connecticut | 06762 | — |
| Alkermes Investigational Site | Stamford | Connecticut | 06905 | — |
| Alkermes Investigational Site | Washington D.C. | District of Columbia | 20007 | — |
| Alkermes Investigational Site | Atlantis | Florida | 33462 | — |
| Alkermes Investigational Site | Bradenton | Florida | 34209 | — |
| Alkermes Investigational Site | Maitland | Florida | 32751 | — |
| Alkermes Investigational Site | Naples | Florida | 34105 | — |
| Alkermes Investigational Site | Ormond Beach | Florida | 32174 | — |
| Alkermes Investigational Site | Sarasota | Florida | 34233 | — |
| Alkermes Investigational Site | Tampa | Florida | 33634 | — |
| Alkermes Investigational Site | Vero Beach | Florida | 32960 | — |
| Alkermes Investigational Site | Atlanta | Georgia | 30312 | — |
| Alkermes Investigational Site | Atlanta | Georgia | 30327 | — |
| Alkermes Investigational Site | Atlanta | Georgia | 30342 | — |
| Alkermes Investigational Site | Columbus | Georgia | 31904 | — |
| Alkermes Investigational Site | Evanston | Illinois | 60201 | — |
| Alkermes Investigational Site | Des Moines | Iowa | 50314 | — |
| Alkermes Investigational Site | Lenexa | Kansas | 66214 | — |
| Alkermes Investigational Site | Alexandria | Louisiana | 71301 | — |
| Alkermes Investigational Site | Detroit | Michigan | 48202 | — |
| Alkermes Investigational Site | Golden Valley | Minnesota | 55422 | — |
| Alkermes Investigational Site | St Louis | Missouri | 63104 | — |
| Alkermes Investigational Site | St Louis | Missouri | 63110 | — |
| Alkermes Investigational Site | St Louis | Missouri | 63131 | — |
| Alkermes Investigational Site | Albuquerque | New Mexico | 87106 | — |
| Alkermes Investigational Site | Patchogue | New York | 11772 | — |
| Alkermes Investigational Site | Stony Brook | New York | 11794 | — |
| Alkermes Investigational Site | Syracuse | New York | 13210 | — |
| Alkermes Investigational Site | Charlotte | North Carolina | 28203 | — |
| Alkermes Investigational Site | Greensboro | North Carolina | 27405 | — |
| Alkermes Investigational Site | Winston-Salem | North Carolina | 27103 | — |
| Alkermes Investigational Site | Canton | Ohio | 44718 | — |
| Alkermes Investigational Site | Columbus | Ohio | 43221 | — |
| Alkermes Investigational Site | Dayton | Ohio | 45417 | — |
| Alkermes Investigational Site | Oklahoma City | Oklahoma | 73104 | — |
| Alkermes Investigational Site | Charleston | South Carolina | 29406 | — |
| Alkermes Investigational Site | Greer | South Carolina | 29650 | — |
| Alkermes Investigational Site | Old Point Station | South Carolina | 29707 | — |
| Alkermes Investigational Site | Spartanburg | South Carolina | 29307 | — |
| Alkermes Investigational Site | Franklin | Tennessee | 37064 | — |
| Alkermes Investigational Site | Knoxville | Tennessee | 37922 | — |
| Alkermes Investigational Site | Dallas | Texas | 75231 | — |
| Alkermes Investigational Site | Houston | Texas | 77030 | — |
| Alkermes Investigational Site | Houston | Texas | 77074 | — |
| Alkermes Investigational Site | Newport News | Virginia | 23601 | — |
| Alkermes Investigational Site | Richmond | Virginia | 23226 | — |
| Alkermes Investigational Site | Seattle | Washington | 98101 | — |
| Alkermes Investigational Site | Seattle | Washington | 98122 | — |
| Alkermes Investigational Site | Seattle | Washington | 98133 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03093324, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 14, 2020 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03093324 live on ClinicalTrials.gov.